CH50 Activity and its Relationship to Antimüllerian Hormone in Patients with Infertility| Stephy Publishers
Current Investigations in Clinical and Medical Research - (CICMR)| Stephy Publishers
Abstract
Objective: To study the importance of immunological screening (CH50, C3, C4) to
determine the correlation between the ovarian reserve and complement pathway.
Design: A cross-sectional multivariate study.
Setting: Single tertiary referral center.
Patients: 40 Women with infertility diagnosis who underwent In Vitro
Fertilization (IVF).
Intervention(s): Basal blood samples collected to measure complement pathway
and antimüllerian hormone.
Main Outcome Measure(s): To correlate complement pathways (CH50 levels) with
AMH. Results: The complement system and ovarian reserve were studied in 40
women aged from 28-48 years (mean=37.87 years), finding the values of CH50
65-268 CAE (mean=153.2 CAE), C3 13.9- 183mg/dl (mean=128.52mg/dl), C4
11.5-106mg/dl (mean=29.86mg/dl), AMH 0.10-3.9ng/dl (mean=1.32ng/dl). A
multivariate analysis comparison was also conducted yielding significant.
Results: negative correlation
between AMH and age (Spearman correlation -0.6; P=0.001), as well as between
AMH and CH50 (Spearman correlation -0.4; P=0.0129).
Conclusion: High CH50 levels are
correlated with an AMH decrease and it could be accordingly associated with
age-related chronic inflammation. Capsule: High levels of CH50 are correlated
with a decrease in AMH levels and could also be considered as a marker of poor
response in IVF cycles.
Keywords: CH50, AMH, Immune
infertility, Complement pathways, ovarian reserve
Introduction
In modern age, behavior and lifestyle have changed dramatically due to
modifications in fertility factors. Advanced maternal age, inflammatory
alterations, and concomitant diseases can change fertility rate over time. We
can use the ovarian reserve as a fertility predictor since it is a concept that
reflects the quality and quantity of oocytes present in the ovary.1,2 In
addition to measuring AMH to quantify the ovarian reserve other basal serum
markers can be taken into account: inhibition B, follicle-stimulating hormone
(FSH), and estradiol, as well as ultrasonographic markers such as ovarian
volume measurement or antral follicle count (AFC).1 AMH is a dimeric
glycoprotein, discovered in the 1940s, that participates in sexual
differentiation, and was found in human follicles in 1990. It is produced by
developing follicle granulosa cells and with clear clinical significance in
ovarian function and reserve.2 Clinical applications of AMH serum measurement
include menopause prediction in different patient groups, for example
In modern age, behavior and lifestyle have changed dramatically due to
modifications in fertility factors. Advanced maternal age, inflammatory
alterations, and concomitant diseases can change fertility rate over time. We
can use the ovarian reserve as a fertility predictor since it is a concept that
reflects the quality and quantity of oocytes present in the ovary.1,2 In
addition to measuring AMH to quantify the ovarian reserve other basal serum
markers can be taken into account: inhibition B, follicle-stimulating hormone
(FSH), and estradiol, as well as ultrasonographic markers such as ovarian
volume measurement or antral follicle count (AFC).1 AMH is a dimeric
glycoprotein, discovered in the 1940s, that participates in sexual
differentiation, and was found in human follicles in 1990. It is produced by
developing follicle granulosa cells and with clear clinical significance in
ovarian function and reserve.2 Clinical applications of AMH serum measurement
include menopause prediction in different patient groups, for example
To read more #MedicalResearch
https://www.stephypublishers.com/cicmr/fulltext/CICMR.MS.ID.000513.php
For more #Openaccessjournals
https://www.stephypublishers.com/
Comments
Post a Comment